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Abstract 
 
Whilst most adult patients with acute lymphoblastic leukaemia will go into remission with standard induction 
chemotherapy, many will relapse. Response rates to standard salvage chemotherapy regimens are low and the 
outlook on relapse is very poor and associated with significant morbidity and mortality hence the need for newer 
targeted approaches. Inotuzumab ozogamicin (previously known as CMC-544) is an antibody-drug conjugate and 
consists of a monoclonal anti-CD22 antibody bound to calicheamicin. The target, CD22, is widely expressed on acute 
lymphoblastic leukaemia cells making it a potential therapeutic target. The calicheamicin is delivered intracellularly 
and causes leukaemia cell apoptosis. Overall response rates of 57% were observed in a Phase II study and the final 
results of a Phase III randomised controlled trial comparing this drug to the investigator choice ‘standard of care’ 
chemotherapy are eagerly awaited. Whilst initial results are promising, there have been concerns regarding liver 
toxicity and the incidence of veno-occlusive disease of the liver especially in patients who have previously received or 
go on to allogeneic stem cell transplant.  
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Introduction 
  
Adult Acute Lymphoblastic Leukaemia (ALL) is a relatively rare disorder with an incidence of between 1.0 and 1.7 new 
cases per year per 100,000 population (1)(2). Initial response to treatment is usually favourable with remission rates 
from standard induction chemotherapy around  85 to >90% (3) (4)  but overall 5 year survival rates are only 40-
50%(3) (4). Current issues in the management of adult ALL include treatment related toxicity, selection of patients for 
allogeneic transplant and most importantly the poor outcome of relapsed disease. 
  
Relapsed or refractory ALL represents a challenging situation with no successful standard of care chemotherapy 
treatment. Overall survival rates are low between 7% and 24%(5),(6). Conventional chemotherapy regimens used 
include FLAG (+/-Idarubicin), high dose cytarabine based regimens and Clofarabine based regimens. For those with 
later relapses (usually 18 to 24 months from diagnosis) standard Induction regimens can be repeated but there are 
concerns about toxicity arising from cumulative anthracycline doses. Response rates to these treatments are 
disappointingly low at around 36-48% (6). Ultimately for the patients who are fit enough, where a suitable donor is 
found the aim is to proceed to allogeneic stem cell transplant (SCT). Survival rates in this setting have been reported 
between 16-23% with SCT(5) (6) and only 4% following chemotherapy(5). Those patients who relapse after SCT fare 
significantly worse and again there is no standard therapeutic approach. 
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The poor response rates to standard chemotherapy approaches in relapsed ALL have led to trials looking for newer 
targeted approaches especially with monoclonal antibody based treatments or T cell engaging strategies. 
Blinatumomab is a bi-specific antibody targeting CD19 and CD3. A Phase II study investigating Blinatumomab in 
patients with relapsed/refractory ALL showed responses (Complete response or complete response with partial 
haematologic recovery) in 25 out of 36 (69 %) patients(7).  The results of a larger Phase III study comparing 
Blinatumomab to ‘standard of care chemotherapy’ (The Tower Study)(8) are awaited. Chimeric antigen receptor T 
cells are T cells which have been genetically modified to express anti-CD19. They have been shown in small numbers 
of children and adults to produce complete remission rates of 90% in patients with relapsed/refractory ALL (9) 
However there are concerns around the high incidence of severe cytokine release syndrome necessitating the use of 
the IL-6 antagonist Tociluzumab in over a quarter of patients. This is also not a uniform technology with a variety of 
viral vectors and co-stimulatory domains being tested. Inotuzumab is the focus of this review and therefore 
Blinatumomab and chimeric antigen receptor T cells will not be considered further.  
 
 
Inotuzumab ozogamicin 
 
Inotuzumab ozogamicin (Previously known as CMC-544) is an antibody drug conjugate and consists of a  monoclonal 
anti-CD22 antibody bound to calicheamicin (10). The target, CD22, is a member of the immunoglobulin superfamily 
and is found on mature B cells and to a lesser extent immature B cells. It is a particularly promising target because of 
its widespread expression on B cells. A study of CD22 expression in children and young adults with relapsed or 
refractory ALL showed expression in all patients and in  ≥ 90% of cells in 155 out of 163 (95%) patients. Density of 
CD22 expression was noted to be lower in patients with MLL gene rearrangement although the significance of this is 
not known. Levels of soluble CD22 were also noted to be low in both blood and bone marrow(11). However neither 
the intensity of CD22 antigen expression that constitutes positivity is clear nor the percentage of cells that need to be 
positive to make those cells a target for the antibody. Antibody bound CD22 is usually internalised rather than shed 
so the caliceamicin is delivered and released intracellularly (12). Calicheamicin is a product of the bacteria 
Micromonospora echinospora and is cytotoxic. Calicheamicin binds to DNA causing dsDNA breaks leading to cell 
death (10). It would therefore appear to be a potentially effective treatment for malignant B cell disorders.  
 
Dosing 
  
A Phase I dose escalation study of Inotuzumab given every 3-4 weeks in 79 patients with relapsed B cell lymphoma 
was performed to investigate the maximum tolerated dose (MTD) and safety. An MTD of 1.8mg/2 was suggested 
(13). During this study the interval of dose administration was increased from three to four weeks to allow time for 
platelet count recovery. There has also been a suggestion that lower doses given more frequently may be more 
effective and associated with less toxicity and so Inotuzumab at a dose of 0.8mg/m2 on day 1 and 0.5mg/m2 on Day 8 
and Day 15 has also been used (14). 
 
Inotuzumab levels have also been studied and found to correlate with response. (15) In a Phase II study Inotuzumab 
levels at 3 hours post infusion >100ng/mL CR was seen in 8/9 patients (89%) compared with 5 of 15 (33%) with levels 
less than 100ng/mL (p=0.008). The reason for differing post infusion levels in patients is not known. 
 
Toxicity 
  
Inotuzumab is usually given as an intravenous infusion over 1 hour with premedication consisting of oral 
paracetamol, intravenous antihistamine and corticosteroid to reduce the incidence of infusion related events. Despite 
this there is a reported incidence of drug related fever, Grade 1-2 in 40% of patients and Grade 3 or 4 in 20% of 
patients (15). Drug related hypotension is also seen but is usually milder with 24% of patients experiencing grade 1 to 
2 reactions (15).  
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Initial safety data from 79 patients treated for relapsed non-Hodgkin’s Lymphoma in a Phase I dose escalation study 
of Inotuzumab given every 3-4 weeks showed that the most common adverse event (AE) in patients receiving the 
MTD was low platelets with  nearly 90% of patients experiencing any grade and >30% severe (Grade 3 or 4) 
thrombocytopaenia. Neutropaenia and transaminitis was also seen but to a lesser extent. One patient had veno-
occlusive disease of the liver (VOD) (but had been noted to had a previous VOD like illness, had had a previous 
autologous transplant and previous radiotherapy involving the liver). (13). Further studies in patients with ALL have 
shown similar results (14,15). Provisional data published in abstract form from the Phase 3 study showedGrade>/=3 
hepatobiliary in 9% and any grade VOD in 15/109 patients (16). When used in elderly patients with ALL in 
combination with low intensity chemotherapy (mini-hyper-CVAD) high numbers of Grade ≥ 3 toxicities were seen, 
especially infections (88%), thrombocytopaenia (76%) and increased bilirubin (24%) (17). However it is not possible to 
determine whether this increased toxicity is due to patient age or concurrent chemotherapy. It is likely that it is a 
combination of both. 
 
 
Results of Inotuzumab in Acute Lymphoblastic Leukaemia 
 
 A Phase II study performed at the MD Anderson Cancer Centre explored the use of Inotuzumab Ozogamicin in 49 
adults and children with relapsed and refractory ALL(15). The median age was 36 years (range 6-80 years) and 
patients had to have CD22 expression of at least 20% as assessed by flow cytometry to be eligible.  For 13 patients 
this was the first salvage regimen, 24 second and 12  ≥  3rd salvage regimen. Responding patients were permitted to 
proceed to allogeneic transplant. Inotuzumab ozogamicin was given at a dose of 1.8mg/m2 as an intravenous infusion 
over 1 hour at an interval of 3-4 weeks. Pre-medication was with oral paracetamol and intravenous antihistamine and 
corticosteroid. Patients with stable or progressive disease (who were CD20 positive) were also given Rituximab (9 out 
of 49 patients). A maximum of 4 cycles of Inotuzumab was given. The overall response rate was 57% with 28 out of 49 
patients responding. 19/49 (39%) of patients had resistant disease. Patients who were Philadelphia chromosome 
positive were less likely to respond although the difference in response rates was not statistically significant. Minimal 
residual disease (MRD) by flow cytometry was assessed in 27 patients achieving CR/CRp (For definitions see Table 1), 
and was negative in 17 (63%) patients. The median overall survival in this study was 5.1 months. Attaining MRD 
negativity was not associated with improved survival.  
Twenty two patients  proceeded to allogeneic transplant (19 in remission 3 with active disease) with a variety of 
conditioning regimens (most commonly  Busulfan + clofarabine in 8). 5 of 23 (23%) had clinical evidence of veno-
occlusive disease  (2 biopsy proven), 4 of whom died. There were also five deaths from infection. The duration of 
complete response was short including the 22 patients who underwent SCT (median survival 5.2 months). Of those 
transplanted 9 were still alive and free from relapse at the time of publication however longer term follow-up will be 
required to see if those remissions are durable. 
Significant adverse events included myelosuppression and related events (especially bacterial infections and 
pneumonia). Grade 1-4 drug related fever was seen in 29 (59%) patients and was severe (Grade 3 to 4) in 9. Minor 
elevation of liver enzymes were also commonly seen 27 (55%) grade 1-2 but were less commonly severe (1 patient, 
grade 3). Mild (Grade 1or 2) bilirubin increases were seen in 12 (24%) patients and 2 (4%) patients had a more 
significant (Grade 3) rise. 
 
A further 41 patients were studied in addition to the 49 described above but were treated with a weekly schedule of  
Inotuzumab at a dose of 0.8mg/m2 on day 1 and 0.5mg/m2 on Day 8 and Day 15 (14). Again this was a group of 
patients with heavily pre-treated relapsed/refractory ALL. Overall 17 (19%) experienced a CR, 27 (30%) CRp and 8 
(9%) CRi giving an overall response rate of 58%. Response rates were similar in both the weekly and single dose 
groups. Negative MRD by flow cytometry was seen in 36 of 50 responding patients. 34 (38%) patients had resistant 
disease. The median overall survival was 6.2 months (5.0 months with single dose schedule and 7.3 months with 
weekly dose schedule). The median duration of remission was 7 months. Toxicity was reduced in the weekly group 
with less fever, hypotension and liver function abnormalities. 
 
Inotuzumab has also been studied in combination with reduced intensity chemotherapy (mini hyper CVD) in patients 
aged >60yrs with newly diagnosed ALL. Preliminary results from 33 patients were published in Abstract at EHA 2015 
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with 29/30 evaluable patients attaining CR or CR with incomplete platelet recovery (17). There were significant levels 
of Grade 3 or 4 toxicities mainly infective and haematologic. Grade 2 VOD was seen in 2 (7%) patients. Historical 
comparison to Hyper CVAD+/- Rituximab suggested improved overall survival rates with 2 year survival rates of 78% 
compared with 38%. 
 
The MD Anderson Cancer Centre reported retrospectively on the use of Inotuzumab in patients under 18 years of age 
who were refractory to conventional salvage chemotherapy for relapsed ALL. The dose used was initially 1.3mg/m2 
and subsequently 1.8mg/m2 per cycle up to a maximum of 8 cycles. Initially the dose was given every 3 weeks but 
later as a weekly divided dose. Five patients were treated with no response seen in two. The other three patients had 
a CR (two with incomplete platelet recovery). Three patients proceeded to transplant, one of whom developed VOD 
having received busulphan and clofarabine conditioning (18). 
 
 
Global Phase III Clinical Trial of Inotuzumab 
  
This is an open-label, randomized phase III study of Inotuzumab Ozogamicin compared to a pre-defined investigator’s 
choice in adult patients with relapsed or refractory CD22-positive Acute Lymphoblastic Leukemia (ALL)(19). Standard 
of care chemotherapy (SOC) options included FLAG, High dose cytarabine or cytarabine and Mitoxantrone based 
chemotherapy. Provisional results were presented as a Late Breaking Abstract at the European Haematology 
Association Annual Meeting 2015 (16). Inotuzumab was given at a dose of 1.8mg/m2 per cycle at three or four week 
intervals up to a maximum of 6 cycles. The two primary endpoints were complete remission +/- incomplete 
haematologic recovery and overall survival. In total 326 patients were entered. An analysis of the first 218 patients 
randomised showed a significant improvement in CR/CRi rates of 80.7% compared with 33.3% (p<0.0001). Improved 
rates of minimal residual disease (MRD) negativity in those with CR/CRi were also seen 78.4% versus 28.1%  
(p<0.0001). More patients in the Inotuzumab arm proceeded to transplant, 48 compared with 20 in the SOC arm. 
However whilst response rates were improved including MRD negativity duration of remission was short in both arms 
(4.6 months versus 3.1 months p=0.0169). 
Grade ≥3 hepatobiliary toxicity was seen in 9% vs 3% and VOD was seen in 13 patients compared with 1 patient in the 
standard of care arm. 5 of the veno-occlusive disease cases happened during treatment and 10 after subsequent 
transplant. 2 fatalities due to VOD were reported. Further results including comparison of survival in the 2 groups are 
keenly awaited and are expected to be available early in 2016. 
 
 
Potential Interaction with transplant 
  
Kebriaei et al from the MD Anderson reported the outcome of 26 patients transplanted between September 2010 
and October 2011 following achieving complete remission with Inotuzumab given for primary refractory or multiply 
relapsed ALL. Conditioning regimens included cyclophopsphamide or etoposide + TBI, clofarabine and busulphan and 
fludarabine melphalan +/-Thiotepa. In 85% of patients the regimen was considered to be myeloablative. 9 patients 
were considered to have high risk cytogenetics and patients had previously received a median of three lines of 
salvage chemotherapy.The results showed an Event Free Survival (EFS) of 30% at 6 months and 22% at 1 year with an 
OS of 20% at 1 year (20). Further follow up is required to determine if these patients will be cured. 
Five patients had fatal VOD at a median of 23 days post SCT following a variety of conditioning regimens. Diffuse 
alveolar haemorrhage seen in 4 patients. The non relapse mortality was 60% at 1 year indicating that toxicity is an 
issue. Disease recurrence accounted for 8 deaths (20) 
Clearly this is a very high risk group of patients but the excessive toxicity dose raise the issue of the problem of veno-
occlusive disease of the liver in patients who have received Inotuzumab.  Baseline VOD rates are thought to range 
between 0-30% of all patients depending on the use of TBI, intensity and hepatotoxic components of the preparative 
regimen and previous liver toxicity. 
 
 
The VOD issue 
D
ow
nl
oa
de
d 
by
 [1
94
.17
6.1
05
.16
6]
 at
 01
:30
 14
 D
ec
em
be
r 2
01
5 
 
Veno-occlusive disease is a clinically diagnosed syndrome characterised by jaundice, tender hepatomegaly and weight 
gain due to fluid retention. The precipitating events appear to be sinusoidal endothelial cell and hepatocyte injury 
resulting from chemotherapy and radiotherapy usually as part of stem cell transplant conditioning regime. As a result 
of this, micro-thromboses form in the hepatic venules and sinusoids contributing to obstruction of portal flow, portal 
hypertension and ascites. Fibrosis of venule walls and sinusoids may occur in some patients and appear to be an 
important determinant of outcome. Known risk factors include previous SCT, conditioning regimens using Busulphan 
or Total Body Irradiation (TBI) and previous liver injury. Obtaining a liver biopsy in suspected patients isn’t always 
feasible for clinical reasons but histological changes seen include centrilobular necrosis and hepatic congestion.  It is a 
potentially fatal complication in patients receiving SCT but has also been seen in patients receiving treatment for 
acute leukaemia/high risk MDS but who have not been transplanted.  
 
Data from a related calicheamicin containing drug 
 
Mylotarg® or Gemtuzumab Ozogamicin (GO) is a monoclonal anti CD33 antibody conjugated to calicheamicin and so 
may provide insight and experience into this issue with Inotuzumab. This is a drug used in the treatment of acute 
myeloid leukaemia (AML). It too has been observed to be associated with transaminitis, raised bilirubin levels and 
VOD. The mechanism of VOD in patients receiving GO is not fully understood, 
 
Giles et al studied the incidence of VOD in 119 patients receiving Myelotarg based regimens but not SCT for high risk 
MDS and AML. VOD was diagnosed clinically using the Seattle and Baltimore criteria. 14/119 (12%) of patients 
developed VOD. VOD was also considered to be the main cause of death in 5 of these patients (21).   
 
The Research on Adverse Drug Events and Reports reviewed the incidence of VOD and suggested a rate of 9% in 
patients receiving GO who did not receive a transplant and that this was increased when followed by SCT and was 
especially high when GO was administered within 3/12 of allo SCT (22).  
 
In a retrospective study from the Dana-Farber Cancer Institute 62 patients with MDS/AML receiving Allo SCT were 
assessed for VOD using the Baltimore clinical criteria. 14 of these patients had received GO prior to SCT. 13/62 
patients were diagnosed with VOD. 9/14 (64%) had GO exposure and 4/48 (8%) were without prior GO exposure 
indicating that patients receiving GO prior to SCT are at increased risk of developing VOD (23).  
However concerns regarding GO and liver toxicity  / VOD are not always consistent between studies. The United 
Kngdom Medical Research Council AML15 Trial contained 1113 patients with AML randomised to received GO in 
induction alongside either DA3+10 or FLAG-Ida chemotherapy and again in consolidation phase 948 patients were 
randomised to receive GO or not alongside MACE or Ara-C 1.5g/m2 or 3.0g/m2. In this study GO was used at a dose 
of 3mg/m2 on Day 1. It showed no excess of non-haematologic toxicity in induction and no increase in liver toxicity 
overall or in patients proceeding to SCT within 120 days (24). This raises the issue of whether hepatic toxicity/VOD is a 
dose effect. 
 
Strategies to avoid this potentially fatal complication might include careful selection of patients avoiding those who 
have previously had liver injury, the use of prophylactic defibrotide (although this is unproven therapy) and the use of 
conditioning regimens which are known to have a reduced risk of VOD. 
 
 
Expert commentary and five year view 
 
With overall response rates of 57-80% this is a drug with clear evidence of efficacy in patients with relapsed Acute 
Lymphoblastic Leukaemia and in 5 years is likely to be a standard of care treatment for relapsed ALL in adults. The 
question arises as to how it can be best used both safely and appropriately. If used in relapsed disease where the 
intention is to proceed to allogeneic stem cell transplant then its use might be restricted by the risk of VOD. Further 
information regarding this risk will be helpful and consideration will have to be given to careful patient selection, 
close monitoring for VOD and prompt treatment of what potentially is a fatal complication. Another consideration 
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will be the choice of dosing schedule with a suggestion that with a weekly dosing schedule the toxicity is reduced 
without compromising the efficacy. Its use in molecular failure is more uncertain as the data for Blinatumomab are 
better defined. Other possible uses are in patients with primary refractory disease and those who relapse post 
allogeneic transplant but again there will be concerns in these two difficult groups of patients about the risk of VOD 
and also the durability of responses. This drug will also need to be compared with Blinatumamab and chimeric 
antigen receptor T cells in terms of efficacy and toxicity as all three have evidence of efficacy but concerns regarding 
toxicity. It will also need to be tested in the paediatric population. 
 
Consideration will also have to be given to how best to incorporate this drug into frontline clinical trials in newly 
diagnosed patients. Although the limited data available in the elderly is encouraging concerns regarding 
haematologic, infective and liver toxicity when given alongside chemotherapy are present in this setting. 
 
Current clinical trials investigating Inotuzumab in ALL include; a Phase I/II  studying 2 different doses of Inotuzumab  
in combination with chemotherapy as frontline treatment in the elderly (25), a Phase 1/2 study in combination with 
Bosutinib in patients with Philadelphia chromosome positive ALL and CML in  lymphoid blast crisis (26), a Phase I 
study in combination with CVP (cyclophosphamide, vincristine and prednisone) for patients with relapsed/refractory 
CD22 positive Acute Leukaemia (27) and a study investigating Inotuzumab in combination with Fludarabine and 
Bendamustine for CD22 positive malignancies prior to allogeneic transplant (28). The results of these studies are 
awaited with interest. 
 
 
Key issues 
 
 Most adult patients with ALL will go into remission with standard induction chemotherapy but many will 
relapse. 
 Response rates to standard salvage chemotherapy regimens are low and the outlook in relapse is very poor 
and associated with significant morbidity and mortality hence the need for newer targeted approaches.  
 Inotuzumab ozogamicin (Previously known as CMC-544) is an antibody drug conjugate and consists of a 
monoclonal anti-CD22 antibody bound to calicheamicin.  
 The target, CD22, is widely expressed on Acute Lymphoblastic Leukaemia cells making it a potential 
therapeutic target.  
 Overall response rates of 57% were seen in a Phase II study and final results of a Phase III randomised 
controlled trial comparing this drug to investigator choice ‘standard of care’ chemotherapy are awaited.  
 Whilst initial results are promising there have been concerns regarding liver toxicity and the incidence of 
veno-occlusive disease of the liver especially in patients who have previously received or go on to allogeneic 
stem cell transplant.  
 This drug is likely to become a standard of care treatment for relapsed ALL in adults 
 Future studies investigating the role of this drug in the front line setting are needed. 
 
 
Financial and competing interests disclosure 
 
 
NJ Morley has served on the advisory boards for Roche and Amgen. D Marks has served on the advisory boards and 
consulted for Pfizer and Amgen. The authors have no other relevant affiliations or financial involvement with any 
organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in 
the manuscript apart from those disclosed. 
 
 
 
 
 
D
ow
nl
oa
de
d 
by
 [1
94
.17
6.1
05
.16
6]
 at
 01
:30
 14
 D
ec
em
be
r 2
01
5 
 
 
 
 
 
 
 
 
References 
 
1.  Acute lymphoblastic leukaemia (ALL) incidence trends over time. Available at: www.cancerresearchuk.org/ 
[Last accessed 9 December 2015]  
 
2.  SEER Stat Fact Sheets: Acute Lymphocytic Leukemia (ALL). Available at 
www.seer.cancer.gov/statfacts/html/alyl.html [Last accessed 9 December 2015] 
 
3.  Rowe JM, Buck G, Burnett AK, Chopra R, Wiernik PH, Richards SM, et al. Induction therapy for adults with 
acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL 
XII/ECOG E2993. Blood 2005;106(12):3760–7.  
 
4.  Larson R a, Dodge RK, Burns CP, Lee EJ, Stone RM, Schulman P, et al. A five-drug remission induction regimen 
with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 
8811. Blood. 1995;85(8):2025–37.  
 
5.  Fielding AK, Richards SM, Chopra R, Lazarus HM, Litzow MR, Buck G, et al. Outcome of 609 adults after relapse 
of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood 2007;109(3):944–50.  
 
6.  Gökbuget N, Stanze D, Beck J, Diedrich H, Horst H-A, Hüttmann A, et al. Outcome of relapsed adult 
lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance 
of stem cell transplantation. Blood; 2012;120(10):2032–41.  
 
7.  Topp MS, Gokbuget N, Zugmaier G, Klappers P, Stelljes M, Neumann S, et al. Phase II Trial of the Anti-CD19 
Bispecific T Cell-Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With 
Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia. J Clin Oncol. 2014;32(36):4134–40.  
 
8.  Phase 3 Trial of Blinatumomab vs Investigator’s Choice of Chemotherapy in Patients With Relapsed or 
Refractory ALL, NCT020131. Available from: www.clinicaltrials.gov [Last accessed 9 December 2015] 
 
9.  Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia. NEJM 2014;371:1507-17. 
 
10.  Pfizer. Inotuzumab ozogamicin Fact Sheet. 2012. Available at: 
www.pfizer.com/files/news/asco/inotuzumab_fact_sheet.pdf [Last accessed 9 December 2015]. 
 
11.  Shah NN, Stevenson MS, Yuan CM, Richards K, Delbrook C, Kreitman RJ, et al. Characterization of CD22 
D
ow
nl
oa
de
d 
by
 [1
94
.17
6.1
05
.16
6]
 at
 01
:30
 14
 D
ec
em
be
r 2
01
5 
expression in acute lymphoblastic leukemia. Pediatr Blood Cancer 2015;62(6):964–9. 
 
12.  DiJoseph JF, Dougher MM, Kalyandrug LB, Armellino DC, Boghaert ER, Hamann PR, et al. Antitumor efficacy of 
a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of 
calicheamicin, and rituximab against non-Hodgkin’s B-cell lymphoma. Clin Cancer Res. 2006;12(1):242–9. 
 
13.  Advani A, Coiffier B, Czuczman MS, Dreyling M, Foran J, Gine E, et al. Safety, pharmacokinetics, and 
preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell 
non-Hodgkin’s lymphoma: results of a phase I study. J Clin Oncol 2010;28(12):2085–93. 
 
14.  Kantarjian H, Thomas D, Jorgensen J. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in 
refractory and relapsed acute lymphocytic leukemia. Cancer 2013;119(15):2728–36.  
 
15.  Kantarjian H, Thomas D, Jorgensen J, Jabbour E, Kebriaei P, Rytting M, et al. Inotuzumab ozogamicin, an anti-
CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. 
Lancet Oncol 2012;13(4):403–11.  
 
16.  DeAngelo DJ et al. Efficacy and Safety of Inotuzumab Ozogamicin vs Standard of care in salvage 1 or 2 patients 
with Acute Lymphblastic Leukaemia: an ongoing Global Phase 3 Study. Haematologica. 2015;100(S1):LB2073.  
 
17.  Jabbour E et al. Inotuzumab Ozogamicin in combination with low intensity chemotherapy (mini-hyper-CVAD) 
for the front line therapy in elderly patients (>60 years) with acute lymphoblastic leukaemia. Haematologica. 
2015;100(S1):S114.  
 
18.  Rytting M, Triche L, Thomas D. Initial experience with CMC544 (inotuzumab ozogamicin) in pediatric patients 
with relapsed B cell acute lymphoblastic leukemia. Pediatr blood 2014;544:369–72.  
 
19.  A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed 
Or Refractory Acute Lymphoblastic Leukemia. NCT01564784. Available from: www.clinicaltrials.gov [Last 
accessed 9 December 2015] 
 
20.  Kebriaei P, Wilhelm K, Ravandi F, Brandt M, de Lima M, Ciurea S, et al. Feasibility of allografting in patients 
with advanced acute lymphoblastic leukemia after salvage therapy with inotuzumab ozogamicin. Clin 
Lymphoma Myeloma Leuk 2013;13(3):296–301. 
 
21.  Giles F, Kantarjian H, Kornblau S. MylotargTM(gemtuzumab ozogamicin) therapy is associated with hepatic 
venoocclusive disease in patients who have not received stem cell transplantation. Cancer 2001;406–13.  
 
22.  McKoy JM, Angelotta C, Bennett CL, Tallman MS, Wadleigh M, Evens AM, et al. Gemtuzumab ozogamicin-
associated sinusoidal obstructive syndrome (SOS): An overview from the research on adverse drug events and 
reports (RADAR) project. Leuk Res 2007;31(5):599–604. 
 
23.  Wadleigh M, Richardson P, Zahrieh D. Prior gemtuzumab ozogamicin exposure significantly increases the risk 
of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell. Blood 
D
ow
nl
oa
de
d 
by
 [1
94
.17
6.1
05
.16
6]
 at
 01
:30
 14
 D
ec
em
be
r 2
01
5 
2003;102(5):1578–82. 
 
24.  Burnett AK, Hills RK, Milligan D, Kjeldsen L, Kell J, Russell NH, et al. Identification of patients with acute 
myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 
trial. J Clin Oncol 2011;29(4):369–77.  
 
25.  Inotuzumab Ozogamycin in Elderly Acute Lymphoblastic Leukemia (ALL), NCT01371630. Available from: 
www.clinicaltrials.gov [Last accessed 2015 Oct 19] 
 
26.  Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive Philadelphia-
Chromosome (PC) Positive Acute Lymphoblastic Leukemia (ALL) and Chronic Myeloid Leukemia (CML) 
NCT02311998. Available at www.clinicaltrials.gov [Last accessed 19 Oct 2015] 
 
27.  Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory 
Acute Leukemia, NCT01925131.. Available from: www.clinicaltrials.gov  [Last accessed 19 Oct 2015] 
 
28.  CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies, NCT01664910. Available 
at: www.clinicaltrials.gov [Last accessed 19 Oct 2015] 
 
Table 1 Response Criteria 
 
CR   Complete Remission  
Attainment of bone marrow blasts <5% with recovery of platelets to >/= 100 x10 9/L  
and neutrophils to >/= 1.0 x10 9/L 
 
 CRi   Complete remission with incomplete haematologic recovery.  
Same as CR but with platelets to </= 100 x10 9/L and neutrophils to </= 1.0 x10 9/L 
 
 
CRp   Complete remission with incomplete platelet count recovery. 
   Same as CR but with platelets to >/= 100 x10 9/ 
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